Adam J Rose1, Jeff P Sharman, Al Ozonoff, Lori E Henault, Elaine M Hylek. 1. Department of Medicine, Research Unit-Section of General Internal Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA 02118-2644, USA. adamrose@bu.edu
Abstract
BACKGROUND: Among patients treated with warfarin for venous thromboembolism (VTE), cancer patients have more thrombotic and hemorrhagic events than patients without cancer. Is this also the case when cancer patients are anticoagulated for other indications? OBJECTIVE: The objective of the study is to evaluate the effectiveness of warfarin, given for any indication, among patients with cancer in a community setting. METHODS: We identified patients with cancer from a larger prospective cohort of 6,761 patients from 101 clinical sites in the United States, matched to controls without cancer. The proportion of time spent in the therapeutic range, international normalized ration (INR) variability, and the rate of thromboembolic and major hemorrhagic events were compared between the two groups. RESULTS: Ninety-five patients undergoing treatment for cancer were matched to 283 patients without cancer. The cancer group spent less time in the target INR range (54 vs 66%, P < .001) and had more variable INR values (standard deviation around the mean INR value 1.30 vs 0.71, P < .001). There were more thrombotic events in the cancer group than in the control group (5 vs 0 events, P < .001). These analyses were repeated after excluding all of the patients anticoagulated for VTE; the results were unchanged. CONCLUSIONS: Compared to matched controls, cancer patients receiving warfarin spend less time in the target INR range, have more variable INR values, and have more thrombotic events. These effects are not dependent on whether the patient is anticoagulated for VTE or another indication.
BACKGROUND: Among patients treated with warfarin for venous thromboembolism (VTE), cancerpatients have more thrombotic and hemorrhagic events than patients without cancer. Is this also the case when cancerpatients are anticoagulated for other indications? OBJECTIVE: The objective of the study is to evaluate the effectiveness of warfarin, given for any indication, among patients with cancer in a community setting. METHODS: We identified patients with cancer from a larger prospective cohort of 6,761 patients from 101 clinical sites in the United States, matched to controls without cancer. The proportion of time spent in the therapeutic range, international normalized ration (INR) variability, and the rate of thromboembolic and major hemorrhagic events were compared between the two groups. RESULTS: Ninety-five patients undergoing treatment for cancer were matched to 283 patients without cancer. The cancer group spent less time in the target INR range (54 vs 66%, P < .001) and had more variable INR values (standard deviation around the mean INR value 1.30 vs 0.71, P < .001). There were more thrombotic events in the cancer group than in the control group (5 vs 0 events, P < .001). These analyses were repeated after excluding all of the patients anticoagulated for VTE; the results were unchanged. CONCLUSIONS: Compared to matched controls, cancerpatients receiving warfarin spend less time in the target INR range, have more variable INR values, and have more thrombotic events. These effects are not dependent on whether the patient is anticoagulated for VTE or another indication.
Authors: M Zangari; E Anaissie; B Barlogie; A Badros; R Desikan; A V Gopal; C Morris; A Toor; E Siegel; L Fink; G Tricot Journal: Blood Date: 2001-09-01 Impact factor: 22.113
Authors: G Palareti; C Legnani; A Lee; C Manotti; J Hirsh; A D'Angelo; V Pengo; M Moia; S Coccheri Journal: Thromb Haemost Date: 2000-11 Impact factor: 5.249
Authors: Agnes Y Y Lee; Mark N Levine; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Frederick R Rickles; Jim A Julian; Susan Haley; Michael J Kovacs; Michael Gent Journal: N Engl J Med Date: 2003-07-10 Impact factor: 91.245
Authors: Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami Journal: Blood Date: 2002-07-12 Impact factor: 22.113
Authors: Guy Meyer; Zora Marjanovic; Judith Valcke; Bernard Lorcerie; Yves Gruel; Philippe Solal-Celigny; Christine Le Maignan; Jean Marc Extra; Paul Cottu; Dominique Farge Journal: Arch Intern Med Date: 2002 Aug 12-26